Grant name: Digital Health Technology Derived Biomarkers and Outcome Assessments for Remote Monitoring and Endpoint Development (UG3/UH3 - Clinical Trial Optional)
Funding organization: National Institutes of Health (NIH)
Total funding amount: Not specified
Duration: Maximum of 5 years
Primary objective: Support development and validation of DHT derived biomarkers for clinical trials
Key stakeholders: NIH, patient advocacy organizations, people with lived experience (PWLE)
Significance: Addresses unmet clinical endpoint needs in clinical trials
Grant frequency: New announcement
Higher Education Institutions
Public/State Controlled Institutions of Higher Education
Private Institutions of Higher Education
Nonprofits (with and without 501(c)(3) status)
For-Profit Organizations
Small Businesses
Local Governments
State Governments
County Governments
City or Township Governments
Special District Governments
Indian/Native American Tribal Governments (Federally Recognized and Other)
Federal Government Agencies
U.S. Territories or Possessions
Independent School Districts
Public Housing Authorities/Indian Housing Authorities
Faith-based or Community-based Organizations
Regional Organizations
Non-domestic (non-U.S.) Entities are not eligible to apply.
Non-domestic components of U.S. Organizations are not eligible.
Development and validation of DHT derived biomarkers and clinical outcome assessments.
Focus on three or more diseases or conditions.
Community engagement and input from PWLE required.
Multidisciplinary teams encouraged, including clinical scientists, statisticians, and regulatory experts.
Application budgets are not limited but must reflect actual project needs.
Open Date: January 21, 2025
Application Due Dates: Various deadlines until June 22, 2026
Earliest Start Date: February 21, 2025
Must comply with NIH Grants Policy Statement and other federal regulations.
Applications must follow the instructions in the How to Apply - Application Guide.
A community engagement plan is required.